Atopic Dermatitis

Raj J. Chovatiya, MD, PhD, reviews the clinical manifestations and underdiagnoses of atopic dermatitis.

Oral doses of 3 Janus kinase inhibitors show the therapies out-performed placebo in all outcomes measured in patients with moderate-to-severe AD.

Despite most adverse events of special interest being deemed mild to moderately severe in nature, these types of events have been increasingly reported in real-world practice.

Despite this, close gynecological monitoring of pregnant women with PR was still recommended.

Keratosis pilaris has often been associated with AD and filaggrin loss-of-function mutations, the latter of which are frequent in Europe with an approximate prevalence of 7%

Investigators led by Dr. Bowie deemed it necessary to establish “transparent classification” of topical corticosteroids in the pursuit of stronger and more reliable dermatologic outcomes and treatments.

Though patients with undifferentiated pruritus had higher serum LDH levels, these levels were not associated with an increased risk of hematologic cancer.

Prior to this new data, only 2 studies had evaluated the association between psoriasis and NAFLD in the US.

Investigators suggested that the large number of systemic therapies used when treating HS in these patients indicated referral delays or difficulties in obtaining disease control in those with moderate to severe HS.

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.

Drs Alexandra K. Golant, Raj J. Chovatiya, Linda Stein Gold, and Eric Simpson comment on clinical implications of boxed warnings for the utilization of JAK inhibitors when treating atopic dermatitis.

This approval makes tapinarof cream the first and only FDA-approved steroid-free topical medication in its class.

Korey Capozza, MPH, offers insight into changing public perception of atopic dermatitis and bridging unmet needs in the field.

Taylor and Tina Capps assess the burden of atopic dermatitis on Taylor’s life and the impact on her family.

Despite this, more than half of nurses included in this global survey were not financially compensated for their additional work.

Guselkumab was effective in patients with previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas.

Despite being one of the most common dermatologic conditions, the etiology of chronic pruritis is still unknown, and conventional medication may not always result in a good therapeutic response.

A significant decrease in SII, SIRI, CRP, and UAS-7 was observed in the third month of omalizumab treatment, and the responder groups at 3 and 6 months of treatment had significantly higher baseline SII and SIRI levels than non-responders.

About half of a cohort of nearly 800 patients said they experience ocular symptoms.

Eric Simpson, MD, MCR, leads a discussion on current FDA approved topical and systemic JAK inhibitors for the management of atopic dermatitis.

Alexandra K. Golant, MD, highlights factors to consider when recommending the use of JAK inhibitors to manage atopic dermatitis for various patient populations.

Taylor and Tina Capps comment on Taylor’s experience of treatment regimens early on and the impact of underlying medical conditions on her atopic dermatitis.

Taylor Capps and her mother, Tina Capps, share Taylor’s initial journey with atopic dermatitis and presenting symptoms.

A post-hoc analysis of the VOYAGE study also found that the biologic improved the percent predicted pre-bronchodilator FEV1 in this patient population.

Promising 2-year data for the IL-17 targeting biologic were recently presented at AAD 2022.

Most research into the rare condition is focused on therapies and diagnostics, but investigators say it is important to better understand the disease’s impact on those around the patient.

The new analysis suggests the infections rarely leads to discontinuation in patients with atopic dermatitis.

These new data come as the FDA reviews the new drug application for deucravacitinib which, if approved, would make deucravacitinib the first allosteric tyrosine kinase 2 inhibitor approved for any disease.

Raj J. Chovatiya, MD, PhD, provides an overview of JAK inhibitors and their use in atopic dermatitis treatment.

Alexandra K. Golant, MD; Raj. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss goals of therapy for patients with atopic dermatitis and challenges physicians face in management of the disease.